Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sarepta’s Aftermath: FDA Staff Still Working Together, Califf Says

Nov 16 2016

• By Derrick Gingery

FDA entrance sign 2016

Related Content

FDA Neurology Clinical Team Leader Departure May Be Mountain Disguised As Molehill

Sep 15 2016

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Sep 20 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

HHS Overrules FDA On Plan B OTC, Sends Teva Back To Drawing Board

Dec 07 2011

Political Appointees Shouldn't Influence Approval Decisions, Califf Says

Oct 20 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

Exondys 51’s Development: Was Placebo-Controlled Trial Possible?

Nov 16 2016

Related Companies

Sarepta Therapeutics, Inc.

Teva Pharmaceutical Industries Ltd.

Additional Topics

United States Approvals Drug Review FDA Regulation Neurology BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window